Patents Assigned to Roslin Institute
-
Publication number: 20060105323Abstract: A system for the detection of gene activation events is provided which comprises a nucleic acid construct encoding a protein of the lipocalin protein family and a peptide tag in which the expression of the construct in a cell or in the cells of a transgenic animal demonstrates the activation of a gene or genes of interest, in which the protein expressed is secreted from the cell and in which detection of the peptide tag indicates expression of the construct.Type: ApplicationFiled: July 25, 2003Publication date: May 18, 2006Applicant: Roslin Institute (Edinburgh) Biosciences Ltd.Inventors: Christopher Whitelaw, Anthony Clark, Helen Clark, Wolf Charles Roland
-
Publication number: 20060051813Abstract: A method is provided for the diagnosis of a transmissible spongiform encephalopathy (TSE) or prion disease in an animal which comprises assaying a sample obtained from said animal to determine the number of hematopoietic cells of the erythroid, megakaryocyte or platelet cell lineages in the sample or an expression product thereof.Type: ApplicationFiled: July 1, 2005Publication date: March 9, 2006Applicant: Roslin Institute (Edinburgh)Inventors: Michael Clinton, Gino Miele, Jean Manson
-
Patent number: 6962787Abstract: A method is provided for the diagnosis of a transmissible spongiform encephalopathy (TSE) or prion disease in an animal which comprises assaying a sample obtained from said animal to determine the number of hematopoietic cells of the erythroid, megakaryocyte or platelet cell lineages in the sample or an expression product thereof.Type: GrantFiled: October 31, 2001Date of Patent: November 8, 2005Assignee: Roslin Institute (Edinburgh)Inventors: Michael Clinton, Gino Miele, Jean Catherine Manson
-
Patent number: 6921665Abstract: This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in expression of a cell-surface antigen that can be used to deplete the undifferentiated cells. Model effector sequences encode glycosyl transferases that synthesize carbohydrate xenoantigen or alloantigen, which can be used for immunoseparation or as a target for complement-mediated lysis. The differentiated cell populations produced are suitable for use in tissue regeneration and non-therapeutic applications such as drug screening.Type: GrantFiled: November 26, 2001Date of Patent: July 26, 2005Assignees: Roslin Institute (Edinburgh), Geron CorporationInventors: Jim McWhir, Joseph D. Gold, J. Michael Schiff
-
Publication number: 20030186437Abstract: A method of controlling the differentiation of a cell is provided which comprises modulation of the expression of the gene Raidd in the cell. The method provides a means for preparing or enriching a population of stem cells through modulation of Raidd expression.Type: ApplicationFiled: March 29, 2002Publication date: October 2, 2003Applicant: ROSLIN INSTITUTEInventors: Anthony John Clark, Ricardo Felmer, Simon Horvat
-
Publication number: 20030106081Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: September 5, 2002Publication date: June 5, 2003Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20030101468Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: July 9, 2002Publication date: May 29, 2003Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 6525243Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: August 29, 2000Date of Patent: February 25, 2003Assignees: Roslin Institute, The Minister of Agricultural, Fisheries and Food, Biotechnology & Biological Sciences Research CouncilInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20030037352Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: October 11, 2001Publication date: February 20, 2003Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20020124277Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: November 21, 2001Publication date: September 5, 2002Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20020112254Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: November 21, 2001Publication date: August 15, 2002Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Publication number: 20020056149Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: ApplicationFiled: November 21, 2001Publication date: May 9, 2002Applicant: Roslin Institute (Edinburgh)Inventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 6252133Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the G0 or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.Type: GrantFiled: February 19, 1997Date of Patent: June 26, 2001Assignees: Roslin Institute (Edinburgh), The Minister of Agriculture, Fisheries & Food, Biotechnology & Biological Sciences Research CouncilInventors: Keith Henry Stockman Campbell, Ian Wilmut
-
Patent number: 6147276Abstract: A method of reconstituting a mammalian embryo involves transferring the nucleus from a quiescent donor cell into a suitable recipient cell. The donor cell is quiescent, in that it is caused to exit from the growth and division cycle at G1 and to arrest in the G0 state. Nuclear transfer may take place by cell fusion. The reconstituted embryo may then give rise to one or more mammals. The invention is useful in the production of transgenic mammals as well as non-transgenics of high genetic merit.Type: GrantFiled: February 19, 1997Date of Patent: November 14, 2000Assignees: Roslin Institute (Edinburgh), The Minister of Agriculture, Fisheries & Food, Biotechnology & Biological Sciences Research CouncilInventors: Keith Henry Stockman Campbell, Ian Wilmut